Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Summary

IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB). This is the first in-human study of IMC-I109V in persons with CHB.

Timeline

Start

2020-08-12

Primary completion

2024-09-10

Completion

2024-12-15

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment into the phase 2 portion was never initiated.”

Drugs

Indications